NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
A.O.U. Città della Salute e della Scienza
Fudan University
Cadila Pharnmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
GOG Foundation
Roswell Park Cancer Institute
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Kael-GemVax Co., Ltd.